With more and more concern being placed on our health, more of the focus markets – up and down – is being fixed on health-care related companies. Vaxil Bio Ltd. (TSX VENTURE:VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, will be presenting at the Planet MicroCap Showcase 2020 on Wednesday, with CEO David Goren hosting and answering questions from investors.
Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma and received orphan drug status from the FDA and EMA.
The company continues to develop ImMucintm and is also developing a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation underway at a top US academic and research institution.
VXL shares gained a penny, or 7.4%, to 14.5 cents, on 1.7 million shares.
